Barclays analyst Andrew Lazar raised the firm’s price target on BellRing Brands (BRBR) to $85 from $79 and keeps an Overweight rating on the ...

Dollarama's Q3 results were in line with expectations, showing revenue growth, but a slight decline in gross margins due to ...

Meta shares moved higher Tuesday after setting a record close yesterday, as investors bid up the stock in the aftermath of a solid quarterly earnings report and optimism about the company's AI-related ...

Palantir's Q4 results were astounding, "eviscerating" (their words in the press release) the consensus. I looked that up—it means "disemboweling." Revenue skyrocketed 36% YoYr, and its free cash flow ...

Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in MNDY usually suggests something ...

Rahway, New Jersey-based Merck & Co., Inc. (MRK) functions as a healthcare company. Valued at $252.4 billion by market cap, ...

BofA lowered the firm’s price target on BioNTech (BNTX) to $147 from $150 and keeps a Buy rating on the shares. On the Q4 call, the firm will ...

Innate Pharma (NASDAQ:IPHA – Get Free Report) and Agenus (NASDAQ:AGEN – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based ...

Celestica (NYSE:CLS – Free Report) (TSE:CLS) had its target price raised by Royal Bank of Canada from $115.00 to $140.00 in a research report sent to investors on Friday morning,Benzinga reports.

Nvidia analysts still think, on average, that the price will rise 45%. There are several arguments in favor of this.